CATALYST PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CATALYST PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $119.07M | Mar 15, 2021 |
| FY2020 | Dec 31, 2019 | $102.31M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $500.0K | Mar 16, 2020 |
| FY2017 | Dec 31, 2017 | $0 | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Mar 14, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Mar 14, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Mar 14, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Mar 14, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $588.99M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $491.73M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $398.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $214.20M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $140.83M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $119.07M | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | $30.12M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $30.90M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $28.84M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $12.45M | Mar 16, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.33M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $163.89M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $71.41M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $83.08M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $39.48M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $74.98M | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | $7.93M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $13.63M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $10.96M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($644.5K) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.78M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $195.12M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $86.81M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $101.84M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $52.39M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $41.30M | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | $8.01M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $13.85M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $10.96M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($987.8K) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $12.65M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $93.15M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $19.79M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $16.94M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $16.50M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $18.84M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $19.92M | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | $11.38M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $11.37M | Mar 14, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.75M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $177.74M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $133.71M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $57.09M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $49.63M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $44.23M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $36.88M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $15.88M | Mar 15, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $239.81M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $143.60M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $116.05M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $60.37M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $45.03M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $34.61M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | ($26.15M) | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | ($13.74M) | Mar 18, 2019 |
| FY2013 | Dec 31, 2013 | ($9.88M) | Mar 19, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $556.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $231.0K | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $29.0K | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.02M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $11.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $19.0K | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $92.0K | Mar 15, 2021 |
| FY2017 | Dec 31, 2016 | $96.1K | Mar 14, 2018 |
| FY2017 | Dec 31, 2015 | $23.5K | Mar 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $851.41M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $470.11M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $375.63M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $237.79M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $192.35M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $112.38M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $60.45M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $85.39M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $41.71M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $123.78M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $82.23M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $75.21M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $30.96M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $22.76M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $24.75M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $9.67M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $4.42M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $2.40M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $954.27M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $727.63M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $387.88M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $300.42M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $206.83M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $169.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $87.63M | Mar 15, 2023 |
| FY2021 | Dec 31, 2018 | $50.79M | Mar 16, 2022 |
| FY2020 | Dec 31, 2017 | $80.96M | Mar 15, 2021 |
| FY2018 | Dec 31, 2016 | $39.31M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $474.19M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $285.16M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $121.27M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $49.86M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($26.31M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($53.71M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($128.69M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($160.56M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($126.56M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($108.15M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $709.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $517.55M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $137.64M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $298.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $171.45M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $130.24M | Mar 16, 2022 |
| FY2021 | Dec 31, 2019 | $89.51M | Mar 16, 2022 |
| FY2021 | Dec 31, 2018 | $16.56M | Mar 16, 2022 |
| FY2020 | Dec 31, 2017 | $57.50M | Mar 15, 2021 |
| FY2018 | Dec 31, 2016 | $13.89M | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 16, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 16, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 122.51M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 120.88M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 107.12M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 105.26M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 102.99M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 103.78M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | 103.40M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 102.74M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 102.55M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 82.97M | Mar 14, 2018 |